FAKTOR OPTIONSSCHEIN - IDORSIA | Delayed Deutsche Boerse AG 08:21:29 2024-06-27 EDT | ||
| 0.32 EUR | -3.03% |
|
| Current month | +47.98% | ||
| 1 month | +6.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 0.32 | -3.03% |
| 24-06-26 | 0.33 | +3.13% |
| 24-06-25 | 0.32 | +3.23% |
| 24-06-24 | 0.31 | -6.06% |
| 24-06-21 | 0.33 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 08:21 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | 
BNP Paribas
|
| WKN | PD2P1D |
| ISIN | DE000PD2P1D9 |
| Date issued | 2021-12-10 |
| Strike | 2.058 CHF |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 200 € |
|---|---|
| Lowest since issue | 0.207 € |
| Spread | 0.01 € |
| Spread % | 3.03% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.058
CHF
Average target price
1.692
CHF
Spread / Average Target
-17.76%
- Stock Market
- Certificates
- Certificat
